ISDA

Deposition Date 2014-01-06

Release Date 2014-02-19

Last Version Date 2024-02-28

Entry Detail

PDB ID:

4OAS

Keywords:

ligase/ligase inhibitor

Title:

co-crystal structure of MDM2 (17-111) in complex with compound 25

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.70 Å

R-Value Free:

0.23

R-Value Work:

0.21

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:E3 ubiquitin-protein ligase Mdm2
Gene (Uniprot):MDM2
Chain IDs:A, B (auth: C), C (auth: E)
Chain Length:96
Number of Molecules:3
Biological Source:Homo sapiens

UniProt ID:Q00987 Pfam ID:PF02201 EC:2.3.2.27

Ligand Molecules

2SW

SO4

Primary Citation

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development.

Sun, D, Li, Z, Rew, Y, Gribble, M, Bartberger, M.D, Beck, H.P, Canon, J, Chen, A, Chen, X, Chow, D, Deignan, J, Duquette, J, Eksterowicz, J, Fisher, B, Fox, B.M, Fu, J, Gonzalez, A.Z, Gonzalez-Lopez De Turiso, F, Houze, J.B, Huang, X, Jiang, M, Jin, L, Kayser, F, Liu, J.J, Lo, M.C, Long, A.M, Lucas, B, McGee, L.R, McIntosh, J, Mihalic, J, Oliner, J.D, Osgood, T, Peterson, M.L, Roveto, P, Saiki, A.Y, Shaffer, P, Toteva, M, Wang, Y, Wang, Y.C, Wortman, S, Yakowec, P, Yan, X, Ye, Q, Yu, D, Yu, M, Zhao, X, Zhou, J, Zhu, J, Olson, S.H, Medina, J.C.Show

J.Med.Chem. 57 1454 1472 (2014)

PMID: 24456472 DOI: 10.1021/jm401753e

Abstact

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).

Legend

Protein

Chemical

Disease

Primary Citation of related structures